The Chief Medical Officer of protagonist Therapeutics disposed of 9,514 shares through a direct open-market transaction on January 20, 2026, raising approximately $784,700. This transaction, executed at $82.48 per share, represents a standard tax-withholding-driven sale rather than a signal of